Organogenesis (ORGO) shares rallied 5.3% in the last trading session to close at $5.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.4% gain over the past four weeks.
Shares of the company were high driven by optimism around growth for the drug/biotech sector in the ongoing year.
This regenerative medicine company is expected to post quarterly earnings of $0.08 per share in its upcoming report, which represents a year-over-year change of -46.7%. Revenues are expected to be $121 million, down 1.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Organogenesis, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ORGO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Organogenesis is part of the Zacks Medical - Drugs industry. OptiNose (OPTN), another stock in the same industry, closed the last trading session 4.5% lower at $3.63. OPTN has returned 45.6% in the past month.
For OptiNose
Zacks' Top Picks to Cash in on Electric Vehicles
Big money has already been made in the Electric Vehicle (EV) industry. But, the EV revolution has not hit full throttle yet. There is a lot of money to be made as the next push for future technologies ramps up. Zacks’ Special Report reveals 5 picks investors
See 5 EV Stocks With Extreme Upside Potential >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Organogenesis (ORGO): Free Stock Analysis Report
OptiNose, Inc. (OPTN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
